Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
Look it up: How well did your school do on the spring 2024 state tests?
Recommended
'She made me buy a saw': WRAL Investigates recording of apparent confession connected to Deven double-murder case in Fayetteville
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Achilles Therapeutics Plc
(NQ:
ACHL
)
0.7199
+0.0091 (+1.28%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Sep 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Achilles Therapeutics Plc
< Previous
1
2
3
Next >
ACHL Stock Earnings: Achilles Therapeutics Meets EPS for Q2 2024
August 14, 2024
ACHL stock results show that Achilles Therapeutics met analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines
May 22, 2024
From
Achilles Therapeutics PLC
Via
GlobeNewswire
ACHL Stock Earnings: Achilles Therapeutics Beats EPS for Q1 2024
May 08, 2024
ACHL stock results show that Achilles Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 08, 2024
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Dow Dips Over 200 Points; RPM International Shares Fall After Q3 Results
April 04, 2024
U.S. stocks turned lower toward the end of trading, with the Dow Jones index falling more than 200 points on Thursday. The Dow traded down 0.59% to 38,894.58 while the NASDAQ fell 0.10% to 16,261.88....
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Achilles Therapeutics: Q1 Earnings Insights
May 10, 2023
Via
Benzinga
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
April 04, 2024
Shares of STAAR Surgical Company (NASDAQ: STAA) rose sharply during Thursday’s session after the company issued strong preliminary first-quarter net sales guidance. STAAR Surgical shares jumped 13.3%...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
April 04, 2024
Via
Benzinga
Nasdaq Surges 1%; ConAgra Brands Posts Upbeat Earnings
April 04, 2024
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 150 points on Thursday. The Dow traded up 0.49% to 39,319.03 while the NASDAQ rose 1% to 16,4340. The S&P...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
ACHL Stock Earnings: Achilles Therapeutics Misses EPS for Q4 2023
April 04, 2024
ACHL stock results show that Achilles Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
April 04, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
April 04, 2024
We're diving into the biggest pre-market stock movers that traders are going to want to keep an eye on for Thursday morning!
Via
InvestorPlace
Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights
April 04, 2024
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
April 04, 2024
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference
February 05, 2024
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction
December 18, 2023
Newly developed computational tools and large datasets with low bias will lead to robust neoantigen prediction and improved personalized cancer therapies
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
November 13, 2023
From
Achilles Therapeutics PLC
Via
GlobeNewswire
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
October 23, 2023
Via
ACCESSWIRE
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
September 20, 2023
Via
Investor Brand Network
Exposures
Product Safety
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
September 20, 2023
EQNX::TICKER_START (NASDAQ:GNPX),(OTCQX:RHHBY),(NASDAQ:JAZZ),(NASDAQ:ALXO),(NASDAQ:ACHL) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
12 Health Care Stocks Moving In Thursday's After-Market Session
September 07, 2023
Via
Benzinga
Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
August 04, 2023
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Achilles Therapeutics to Present at Upcoming Conferences
June 12, 2023
From
Achilles Therapeutics PLC
Via
GlobeNewswire
3 Stocks With 1,000% Upside Potential
May 21, 2023
If you're an investor comfortable with speculative bets, analysts are price targeting these stocks with 1000% upside.
Via
InvestorPlace
Achilles Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
May 10, 2023
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Achilles Therapeutics’ New Immunogenicity Prediction Application of its AI-Powered PELEUS™ Platform Uniquely Identifies the Most Potent T Cell Antigens
May 10, 2023
- New AI module delivers a "Target-to-T cell” approach for revolutionizing the identification and prioritization of targets for personalized antigen approaches -
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
April 25, 2023
Achilles ADSs will continue to trade on the Nasdaq Global Select Market at this time, and the Company’s operations are not affected by the receipt of the Notice
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA Status
April 25, 2023
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Achilles Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
April 17, 2023
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Achilles Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Business Highlights
March 07, 2023
From
Achilles Therapeutics PLC
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.